← Leaderboards
Ali I. Fattom
Nabi Biopharmaceuticals
$17,450,692
Attributed
$17,450,692
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $5.5M · FY2013–23$10M$7.5M$5M$2.5M$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$21,308,874 · 5
By mechanism
N01$11,448,024 · 1
U19$3,858,182 · 1
N44$2,995,800 · 1
R44$2,491,448 · 1
N43$299,888 · 1
R43$215,532 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Vaccines”
- Lawrence Corey · Fred Hutchinson Cancer Center$829,044,908
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$556,540,832
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$515,215,260
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
- Dennis R. Burton · Scripps Research Institute$316,106,418
Research focus
VaccinesAdjuvantNanoemulsionAntigensWaterOilsPre-ClinicalInfectionImmune ResponseClinical TrialsSmall Business Innovation Research GrantScale UpPathogenChildSafetyFormulationDrug Addiction AntagonistNicotineImmunityCyclic GmpNational Institute Of Allergy And Infectious DiseaseMeetingsClinical LotCooperative Study
Grant awards (15)
DEVELOPMENT OF NANOVAX TM (OIL IN WATER NANOEMULSION ADJUVANT) FORMULATED ALLERGENS AS INTRANASAL IMMUNOTHERAPEUTIC VACCINES FOR PEANUT ALLERGY.$79,300
N44 · FY2023 · AI · contact PI
DEVELOPMENT OF NANOVAX TM (OIL IN WATER NANOEMULSION ADJUVANT) FORMULATED ALLERGENS AS INTRANASAL IMMUNOTHERAPEUTIC VACCINES FOR PEANUT ALLERGY.$2,916,500
N44 · FY2020 · AI · contact PI
Pre-Clinical Development of a Intranasal Bivalent gD2/gB2 HSV-2 Mucosal Vaccine$998,684
R44 · FY2020 · AI · contact PI
DEVELOPMENT OF NANOVAX TM (OIL IN WATER NANOEMULSION ADJUVANT) FORMULATED ALLERGENS AS INTRANASAL IMMUNOTHERAPEUTIC VACCINES FOR PEANUT ALLERGY.$299,888
N43 · FY2019 · AI · contact PI
Development of a nanoemulsion-adjuvanted prophylactic HSV-2 vaccine$694,683
R44 · FY2018 · AI · contact PI
Development of a nanoemulsion-based vaccine for chlamydia infection$215,532
R43 · FY2018 · AI · contact PI
Development of a Nanoemulsion Adjuvant$3,050,337
N01 · FY2017 · AI · contact PI
Development of a nanoemulsion-adjuvanted prophylactic HSV-2 vaccine$798,081
R44 · FY2017 · AI · contact PI
Development of a Nanoemulsion Adjuvant: HIV elective project$2,381,521
N01 · FY2016 · AI · contact PI
Development of a Nanoemulsion Adjuvant: HIV elective project$500,000
N01 · FY2015 · AI · contact PI
Development of a Nanoemulsion Adjuvant with a Vaccine for Pandemic Influenza$5,516,166
N01 · FY2013 · AI · contact PI
VACCINATION FOR TREATMENT OF NICTOTINE DEPENDENCE$1,157,646
U19 · FY2003 · DA
VACCINATION FOR TREATMENT OF NICTOTINE DEPENDENCE$1,031,569
U19 · FY2002 · DA
VACCINATION FOR TREATMENT OF NICTOTINE DEPENDENCE$817,093
U19 · FY2001 · DA
VACCINATION FOR TREATMENT OF NICTOTINE DEPENDENCE$851,874
U19 · FY2000 · DA